“…Based on the aforementioned and emerging studies and our multidisciplinary experience, we suggest a systematic approach to cardiac consideration before BTK inhibitor treatment initiation. 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 This specifically includes obtaining a clear cardiovascular history, including screening for any evidence of baseline palpitations, dyspnea, exertional chest pain, edema, unexplained syncope, or overt arrhythmias. If there is a concern for arrhythmia or prior electrocardiographic evidence of AF, next-generation BTK inhibitor therapies can be considered.…”